Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement AER guidance questioned

This article was originally published in The Tan Sheet

Executive Summary

FDA should define more clearly elements of its serious adverse event report guidance for dietary supplements, a food and drug attorney says. A. Wes Siegner, of Hyman, Phelps & McNamara in Washington, tells FDA his client Nutraceutical Corp. is concerned about the agency's recommendation that a person responsible for submitting AERs use "diligent efforts" to obtain data from a patient or reporter. Siegner's Nov. 23 1letter says, "If FDA intends to equate 'diligent efforts' with the use of health care practitioners or other methods to elicit the minimum data elements, FDA should" state its expectations. Siegner also takes issue with the agency's definitions of "identifiable patient," "initial reporter" and "serious" AERs in the June 2009 2guidance (3"The Tan Sheet" July 20, 2009)

You may also be interested in...



Final Guidance For Reporting Adverse Events Gets Serious On Definitions

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements

Lauder Q2 Sales Pummeled By China Closures, US Skin-Care Slowdown

The Estee Lauder Companies, Inc. reported a 17% decline in fiscal 2023 second quarter sales due to pandemic-related closures in China as well as a slowdown in orders of US skin-care products. But the company says both its Chinese and US markets should be “growth drivers” in the second half of the year as markets open up and new innovations kick in.

Hyloris Partner Signs To Market Maxigesic IV In Central And Eastern Europe

Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel